Reverse Myocardial Remodeling Following Valve Replacement

After aortic valve replacement, focal fibrosis does not resolve, but diffuse fibrosis and cell hypertrophy regress. As expected, this regression comes with structural and functional improvement that suggest it is a dynamic process. Fibrosis can be measured and quantified with cardiovascular MR, which makes it a potential therapeutic objective.

Remodelado miocárdico reverso luego del reemplazo valvularLeft ventricular hypertrophy is a key process of many cardiomyopathies and results from cell hypertrophy and the expansion of extracellular matrix (interstitial fibrosis). This study looked at whether myocardial hypertrophy and interstitial fibrosis in the context of severe aortic stenosis are a dynamic process that can be reversed.

The study included 181 symptomatic patients with severe aortic stenosis (valve indexed area 0.4 ± 0.1 cm2/m2) scheduled for valve replacement. Patients were assessed with ECG and cardiovascular MR prior procedure (assessing volume, function, local and diffuse fibrosis), with bio markers (Pro BNP and ultrasensitive T troponin) and 6-minute walk test.


Read also: What’s New in the European Guidelines on Peripheral Arterial Disease.


MR was used to measure extracellular volume fraction, deriving matrix mass volume and cell volume. Biopsy ruled out other subjacent heart conditions and all measurements were repeated one year after valve replacement.

116 patients that did not require pacemaker, showed, at one year, a significant improvement of mean gradient (48±16 mm Hg to 12±6 mm Hg; p<0.001) and ventricular mass decreased a significant 19%. Focal fibrosis in MR with gadolinium saw no change but extracellular volume fraction increased thanks to a 16% reduction of matrix volume and a proportionally higher reduction of cell volume.


Read also: ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper.


All these changes were followed by improved diastolic function, reduced Pro BNP levels, improved 6-minute walk test and functional class.

Conclusion

Diffuse fibrosis and cell hypertrophy regress after valve replacement, which brings on structural and functional improvement.

Original title: Reverse Myocardial Remodeling Following Valve Replacement in Patients with Aortic Stenosis.

Reference: Thomas A. Treibel et al. J Am Coll Cardiol 2018;71:860–71.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...